David Abrams - Abrams Capital Management 13F Activity & Position Changes (Q4 2023)

As of Dec 31, 2023, the Abrams Capital Management portfolio activity showed several notable changes in holdings, according to the latest SEC 13F filing reported on Feb 09, 2024. The activity included new positions, additions to existing holdings, reductions, and complete exits, providing a clear view of how the portfolio evolved during the quarter.

During Q4 2023, the filing reported:

New Buys - None reported

Increases - None reported

Reductions - Meta Platforms, Inc., Teva Pharmaceutical Industries , USCB Financial Holdings, Inc.

Complete Exits - None reported

These updates highlight how the portfolio adjusted across different sectors and market conditions, offering insights into allocation shifts and investment trends.

Date	Symbol	Name	Type	Change Qty	% Change	Value	Remaining
Q4 2023	META Meta Platforms, Inc.	Meta Platforms, Inc.	Sell	-216,924	-23.4%	$251.86M	711,550
Q4 2023	TEVA Teva Pharmaceutical Industries	Teva Pharmaceutical Industries	Sell	-1,969,597	-24.7%	$62.61M	5,996,836
Q4 2023	USCB USCB Financial Holdings, Inc.	USCB Financial Holdings, Inc.	Sell	-499,299	-76.9%	$1.83M	149,786